Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs

Gain a deeper understanding of HER2- and TROP2-targeted antibody–drug conjugates (ADCs) in NSCLC, including biomarker testing, mechanism of action for available ADCs, latest clinical data and guideline updates, and patient education on identification and management of ADC-related adverse events. Download the slides and read a clinical commentary from 2 nurse specialists involved in the management of patients with NSCLC.

Share

Program Content

Events

  • Live Event Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs
    Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

ADCs for Advanced NSCLC
The Use of Antibody–Drug Conjugates as Novel Therapies for Patients With Advanced NSCLC: Advanced Practice Professional Considerations
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2024

Expires: September 26, 2025

Faculty

cover img faculity

Blanca Ledezma, MSN, NP-AOCNP

Nurse Practitioner III
Division of Hematology/Oncology
UCLA Santa Monica
Santa Monica, California

cover img faculity

Denise Rouse, MS, PA-C

Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education, in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner